Chronic Losartan Administration Reduces Mortality and Preserves Cardiac but Not Skeletal Muscle Function in Dystrophic Mice by Bish, Lawrence T et al.
University of Pennsylvania
ScholarlyCommons
Departmental Papers (Vet) School of Veterinary Medicine
6-22-2011
Chronic Losartan Administration Reduces
Mortality and Preserves Cardiac but Not Skeletal
Muscle Function in Dystrophic Mice
Lawrence T. Bish
University of Pennsylvania, bish@mail.med.upenn.edu
Mark Yarchoan
Margaret M. Sleeper
University of Pennsylvania, sleeper@vet.upenn.edu
Jeffrey Gazzara
Kevin J. Morine
See next page for additional authors
Follow this and additional works at: https://repository.upenn.edu/vet_papers
Part of the Cardiovascular Diseases Commons, Comparative and Laboratory Animal Medicine
Commons, and the Musculoskeletal Diseases Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/vet_papers/14
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Bish, L. T., Yarchoan, M., Sleeper, M. M., Gazzara, J., Morine, K. J., Acosta, P., Barton, E. R., & Sweeney, H. L. (2011). Chronic
Losartan Administration Reduces Mortality and Preserves Cardiac but Not Skeletal Muscle Function in Dystrophic Mice. PLoS One, 6
(6), e20856-. http://dx.doi.org/10.1371/journal.pone.0020856
Chronic Losartan Administration Reduces Mortality and Preserves
Cardiac but Not Skeletal Muscle Function in Dystrophic Mice
Abstract
Duchenne muscular dystrophy (DMD) is a degenerative disorder affecting skeletal and cardiac muscle for
which there is no effective therapy. Angiotension receptor blockade (ARB) has excellent therapeutic potential
in DMD based on recent data demonstrating attenuation of skeletal muscle disease progression during 6–9
months of therapy in the mdx mouse model of DMD. Since cardiac-related death is major cause of mortality
in DMD, it is important to evaluate the effect of any novel treatment on the heart. Therefore, we evaluated the
long-term impact of ARB on both the skeletal muscle and cardiac phenotype of the mdx mouse. Mdx mice
received either losartan (0.6 g/L) (n = 8) or standard drinking water (n = 9) for two years, after which
echocardiography was performed to assess cardiac function. Skeletal muscle weight, morphology, and
function were assessed. Fibrosis was evaluated in the diaphragm and heart by Trichrome stain and by
determination of tissue hydroxyproline content. By the study endpoint, 88% of treated mice were alive
compared to only 44% of untreated (p = 0.05). No difference in skeletal muscle morphology, function, or
fibrosis was noted in losartan-treated animals. Cardiac function was significantly preserved with losartan
treatment, with a trend towards reduction in cardiac fibrosis. We saw no impact on the skeletal muscle disease
progression, suggesting that other pathways that trigger fibrosis dominate over angiotensin II in skeletal
muscle long term, unlike the situation in the heart. Our study suggests that ARB may be an important
prophylactic treatment for DMD-associated cardiomyopathy, but will not impact skeletal muscle disease.
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Abstract
Duchenne muscular dystrophy (DMD) is a degenerative disorder affecting skeletal and cardiac muscle for which there is no
effective therapy. Angiotension receptor blockade (ARB) has excellent therapeutic potential in DMD based on recent data
demonstrating attenuation of skeletal muscle disease progression during 6–9 months of therapy in the mdx mouse model
of DMD. Since cardiac-related death is major cause of mortality in DMD, it is important to evaluate the effect of any novel
treatment on the heart. Therefore, we evaluated the long-term impact of ARB on both the skeletal muscle and cardiac
phenotype of the mdx mouse. Mdx mice received either losartan (0.6 g/L) (n = 8) or standard drinking water (n = 9) for two
years, after which echocardiography was performed to assess cardiac function. Skeletal muscle weight, morphology, and
function were assessed. Fibrosis was evaluated in the diaphragm and heart by Trichrome stain and by determination of
tissue hydroxyproline content. By the study endpoint, 88% of treated mice were alive compared to only 44% of untreated
(p = 0.05). No difference in skeletal muscle morphology, function, or fibrosis was noted in losartan-treated animals. Cardiac
function was significantly preserved with losartan treatment, with a trend towards reduction in cardiac fibrosis. We saw no
impact on the skeletal muscle disease progression, suggesting that other pathways that trigger fibrosis dominate over
angiotensin II in skeletal muscle long term, unlike the situation in the heart. Our study suggests that ARB may be an
important prophylactic treatment for DMD-associated cardiomyopathy, but will not impact skeletal muscle disease.
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Introduction
Duchenne muscular dystrophy (DMD) is a degenerative
disorder affecting skeletal and cardiac muscle for which there is
no effective therapy [1]. Boys typically present with symptoms of
muscle weakness by age five, become wheelchair-bound by early
to mid teens, and die from respiratory failure or cardiomyopathy
in their late teens to early twenties [2]. One approach to the
treatment of DMD involves modulating muscle repair pathways to
compensate for the rapid pace of muscle turnover [3]. The
inability of muscle regeneration to keep pace with destruction in
DMD leads to fibrosis, a process that is mediated largely by
transforming growth factor beta (TGF-b) [4,5]. Increased TGF-b
signaling has been documented in both the mdx mouse and in the
Golden Retriever models of DMD [5,6].
A recent study demonstrated that antagonism of TGF-b with
losartan, an angiotensin II receptor blocker that is known to
significantly reduce TGF-b activity in a number of disease models
[7,8], for 6–9 months beginning at 6 weeks of age results in
reduced fibrosis in the diaphragm and gastrocnemius muscles and
increased forelimb and hindlimb grip strength compared to
untreated mdx mice. Since losartan is a widely used antihyperten-
sive drug that is known to be safe in humans, this research has
generated interest in using losartan as a treatment for patients with
DMD [9,10]. However, cardiac function and fibrosis was not
assessed in this study. Therefore, to investigate further the
therapeutic potential of losartan in DMD, a disease characterized
by both skeletal muscle and cardiac dysfunction, we sought to
expand on this previous study by evaluating the functional impact
of losartan therapy on both skeletal and cardiac muscle of mdx
mice after two years of treatment.
Methods
Ethics Statement and Animal Use Protocol
All mice were handled in compliance with the Guide for the Care
and Use of Laboratory Animals published by the National Institutes of
Health (NIH publication No. 85–23, revised 1996). All animal
studies were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Pennsylvania (#802238).
Male mdx mice were weaned at four weeks and randomized to
receive standard drinking water (n = 9) or water supplemented
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with losartan (0.6 g/L) (n = 8) [5]. Water was available ad libitum,
and treatment was continued for two years.
Transthoracic Echocardiography
M-mode echocardiography was performed on mice two years
following the inception of losartan treatment under ketamine/
xylazine anesthesia using a 15-MHz phased-array probe connect-
ed to a Sonos 7500 echocardiographic machine (Philips Medical
Imaging, Andover, Massachusetts). In brief, an M-mode cursor
was positioned in the parasternal short-axis view perpendicular to
the interventricular septum and posterior wall of the LV at the
level of the papillary muscles, and M-mode images were obtained
for measurement of LV end-diastolic and end-systolic dimension
(LVDd and LVDs). The percentage of fractional shortening (%FS)
was calculated from the equation%FS = [(LVDd – LVDs)/
LVDd]6100. The end diastolic and end systolic volumes, ejection
fraction, cardiac output and stroke volume were calculated using
the Teicholtz formulas [11]. The same sonographer performed all
the studies and resulting calculations and was blinded to the
treatment groups of the mice.
Muscle Function Analysis
The contractile properties of the soleus, EDL, and diaphragm
were measured. Mice were anesthetized with ketamine/xylazine
(80/10 mg/kg) and exsanguinated. Blood samples were collected,
allowed to clot for 2 hours at room temperature, then centrifuged
at 2000 x g for 20 minutes to isolate serum. Serum was stored at
280uC, and creatine kinase was measured later using the assay
manufactured by Genzyme (Charlottetown, Canada). The EDL,
soleus, and diaphragm were then removed, bathed in an
oxygenated Ringers solution gas-equilibrated with 95% O2, 5%
CO2, and subjected to isolated mechanical measurements using a
previously described apparatus (Aurora Scientific, Ontario,
Canada) [12]. After determining optimum length (Lo) by
supramaximal twitch stimulation, maximum isometric tetanus
was measured.
Histology
Upon completion of muscle function analysis, muscles were
weighed, then rapidly frozen in OCT compound (Tissue Tek,
Torrance, CA) in melting isopentane for morphological analysis.
Ten micron thick sections were cut, and the resulting slides were
stained using standard hematoxylin and eosin (H&E) and
Trichrome stains (Sigma, St. Louis, MO).
Hydroxyproline Analysis
Cardiac and diaphragm fibrosis was assessed by quantifying
tissue hydroxyproline content [13]. Tissue amino acid analysis was
performed by AAA Laboratories (Mercer Island, WA) using a
Beckman 7300 Amino Acid Analyzer coupled with System Gold
software following hydrolysis in 6N-HCl/0.05% Mercaptoetha-
nol/0.02% phenol for 20 hours at 115uC.
Western Blot
Samples obtained for Western blotting were snap-frozen in
liquid nitrogen. Specimens were pulverized, homogenized in 10
volumes of triple-detergent lysis buffer [50 mM Tris, pH 8.0,
0.1% SDS, 1.0% Triton X-100, 0.5% DOC, 5 mM EDTA,
50 mM DTT, 0.4 tablet/10 mL Complete Protease Inhibitor
Cocktail Tablets (Roche, Indianapolis, IN)], and centrifuged at
13,000 rpm for 5 minutes. Protein concentration of the superna-
tant was then determined using the BioRad Protein Assay
(Hercules, CA), and a 50 ug aliquot of each sample was denatured
using an equal volume of 2X sample loading buffer (130 mM Tris,
pH=8.0, 20% glycerol, 4.6% SDS, 2% DTT, 0.02% bromophe-
nol blue) at 100uC (5 min) then fractionated electrophoretically on
a 4–20% SDS-polyacrylamide gel (Lonza, Rockland, ME).
Proteins were then electroblotted onto a polyvinylidene fluoride
membrane (Immobilon-P, Millipore, Bedford, MA) using the iBlot
transfer apparatus (Invitrogen, Carlsbad, CA). The membrane was
subsequently blocked by incubating in Tris-buffered saline
containing 5% nonfat dry milk and 0.05% Tween 20. Immuno-
blotting was performed to detect Nav1.5 (1:100, Abcam, Cam-
bridge, MA); connexin 40 (1:100, Abcam, Cambridge, MA); and
GAPDH (1:2000, Santa Cruz Biotechnology, Santa Cruz, CA).
Detection was performed using the Super Signal West Pico
Chemiluminescent Substrate kit (Pierce, Rockford, IL).
Statistics
Mean values from each experimental group were compared
using the two-tailed Student’s t test or one-way ANOVA with
Student-Neuman-Keuls post hoc analysis as appropriate. The
Kaplan-Meier survival curve was generated using Graph-Pad
Prism software with log-rank analysis (La Jolla, CA).
Results
Study Design and Mortality
Male mdx mice were weaned at four weeks and randomized to
receive either standard drinking water (n = 9) or drinking water
supplemented with losartan (0.6 g/L) (n = 8) for two years [5].
Water was provided ad libitum. By the study endpoint, 88% (7 out
of 8) of treated mice were alive compared to only 44% (4 out of 9)
of untreated mice (Figure 1) (p = 0.05).
Skeletal Muscle Analysis
The extensor digitorum longus (EDL), soleus, and diaphragm
were analyzed at 2 years. There was no significant difference in
mass, length, or cross sectional area in losartan-treated mice vs.
untreated (Figure 2). Furthermore, specific force and maximum
Figure 1. Survival in treated and untreated mdx mice at two
years. The survival curves for treated and untreated mdx mice are
significantly different(p = 0.05). 88% of treated mice were alive at two
years compared to only 44% of untreated mice. Data represent
mean6SEM.
doi:10.1371/journal.pone.0020856.g001
Losartan Preserves Cardiac Function in Mdx Mice
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tetanic force measurements of the EDL, soleus, and diaphragm
muscles were not significantly different in treated vs. untreated
animals (Figure 3).
Hematoxylin and eosin (H&E) and Trichrome staining was
performed on the EDL, soleus, quadriceps, and diaphragm. No
significant differences were noted in terms of the number of
centrally located nuclei (H&E) (data not shown) or extent of
fibrosis (Trichrome) (Figure 4A). Fibrosis was also quantified by
measuring the hydroxyproline content of the diaphragm. Losartan
treatment did not reduce fibrosis as measured by hydroxyproline
content (Figure 4B).
Serum creatine kinase (CK) was measured in losartan-treated
and untreated mice, and no significant difference was noted
between the two groups (data not shown).
Cardiac Muscle Analysis
Cardiac function was assessed via echocardiography. Untreated
mdx mice exhibited left ventricular dilation (i.e, increased left
ventricular inner diameter in diastole and end diastolic volume)
and systolic dysfunction (i.e., decreased ejection fraction and
fractional shortening) at two years, while mdx mice treated with
losartan exhibited preserved cardiac geometry with normal systolic
function (Table 1).
Cardiac fibrosis was assessed by Trichrome stain (Figure 4C)
and quantified by measuring tissue hydroxyproline content. There
was a trend towards reduction of fibrosis with losartan treatment
(p = 0.08) (Figure 4D).
Expression of proteins involved in electrical conduction in the
heart was analyzed by Western blot (Figure 5A). Protein levels of
the sodium channel Nav1.5 were significantly decreased in
untreated mdx hearts compared to healthy C57 mouse hearts;
losartan treatment did not restore Nav1.5 expression in mdx mice
(Figure 5B). Expression of the gap junction protein connexin 40
(Cx40) was increased in untreated mdx hearts compared to healthy
C57 mouse hearts; losartan treatment resulted in normalization of
Cx40 expression (Figure 5C).
Discussion
DMD is an inherited disorder characterized by skeletal muscle
and cardiac pathology for which there is no effective treatment.
Angiotensin receptor blockade (ARB) via losartan has been
proposed to have therapeutic potential for DMD based on recent
data demonstrating attenuation of skeletal muscle disease
progression during 6–9 months of therapy in the mdx mouse [5].
Figure 2. Skeletal muscle morphology in mdx mice at two
years. (a) Mass, (b) length, and (c) cross sectional area of the extensor
digitorum longus (EDL), soleus, and diaphragm were quantified at two
years in treated and untreated mdx mice . No significant differences
were noted. Data represent mean6SD.
doi:10.1371/journal.pone.0020856.g002
Figure 3. Skeletal muscle function in mdx mice at two years. (a)
Specific force and (b) maximum tetanic force of the extensor digitorum
longus (EDL), soleus, and diaphragm were quantified at two years in
treated and untreated mdx mice. No significant differences were noted.
Data represent mean6SD.
doi:10.1371/journal.pone.0020856.g003
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However, cardiac disease was not evaluated in that study. Since
cardiac-related death is major cause of mortality in DMD [2], it is
important to evaluate the effect of any treatment directed at
skeletal muscle on the heart. In this study, we evaluated the long-
term impact of ARB on both the skeletal muscle and cardiac
phenotype of the mdx mouse model of DMD following two years of
losartan treatment. We report that two years of ARB reduced
mortality and preserved cardiac function in mdx mice. However,
we were unable to detect any preservation of function or reduction
of fibrosis in these aged mdx skeletal muscles at two years, contrary
to what was reported in younger mdx mice [5].
Several recent studies have described the phenotype of aged mdx
mice. Van Erp et al followed mdx mice from 3–18 months and
characterized the development of cardiomyopathy during this
period [14]. They found that although cardiac collagen content
and macrophage infiltration was significantly increased by 6
months, basal ventricular function was not significantly decreased
until 18 months. They concluded that this decreased cardiac
function occurs secondary to ongoing cell death, inflammation,
fibrosis, and eventual cardiac remodeling, and they recommend
that studies aimed at evaluating cardiac function in mdx mice
should be performed in animals greater than 18 months old. A
Figure 4. Fibrosis in mdx mice at two years. Trichrome stain was performed and tissue hydroxyproline content was determined to measure
fibrosis in mdx mice at two years. (a) Trichrome stain and (b) tissue hydroxyproline content of the diaphragm, as well as (c) Trichrome stain and (d)
tissue hydroxyproline content of the heart are demonstrated. Note that there was a trend towards reduced hydroxyproline tissue content in the heart
with losartan treatment (p = 0.08). Data represent mean6SD.
doi:10.1371/journal.pone.0020856.g004
Table 1. Cardiac Function As Assessed By 2-D Echocardiography At 2 Years.
HRa(bpm) IVSb(cm) LVIDdc(cm) LVFWd(cm) LVIDse(cm) FSf(%) EDVg(ml) ESVh(ml) EFi(%) LVmassj(g) COk(L/min) SVl(ml)
Conm 3346149n 0.0960.00 0.4060.01 0.1060.01 0.3360.03 1767.9 0.1660.01 0.1060.03 40617 0.7260.02 0.0260.01 0.0660.03
Loso 2826103 0.1160.01 0.3560.04 0.1160.02 0.2160.03 4067.0 0.1160.04 0.0360.01 74610 0.7160.02 0.0260.02 0.0760.05
Pp 0.5026 0.0390 0.0262 0.3556 0.0001 0.0007 0.0388 0.0004 0.0021 0.4798 0.4910 0.6873
aHR: heart rate; bIVS: interventricular septum; cLVIDd: left ventricular inner diameter in diastole; dLVFW: left ventricular free wall; eLVIDs: left ventricular inner diameter in
systole; fFS: fractional shortening; gEDV: end diastolic volume; hESV: end systolic volume; iEF: ejection fraction; jLV: left ventricular; kCO: cardiac output; lSV: stroke
volume; mCon: control treatment; nValues reported as mean 6 standard deviation; oLos: losartan treatment; pp: p value.
doi:10.1371/journal.pone.0020856.t001
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second group followed mdx mice for 20–22 months and evaluated
the cardiac phenotype in untreated mdx mice and in mdx mice
carrying a mini-dystrophin transgene [15]. They found that aged
mdx mice exhibit cardiac fibrosis, ECG abnormalities, systolic
dysfunction, and decreased exercise performance, and they report
that mini-dystrophin expression can partially improve this
phenotype.
Other studies have focused on analysis of the skeletal muscle
phenotype of aged mdx mice. Mouisel et al followed mdx mice for
18–24 months and found that the skeletal muscles of these old
mice were characterized by decreased absolute force, atrophy, and
decreased regenerative capacity compared to 5 month old mdx
mice [16]. Another group used adeno-associated virus to deliver
micro-dystrophin systemically to 20 month old mdx mice and
reported that this approach was effective not only in halting
disease progression but also in improving muscle structure and
function by 24 months, thus demonstrating that it is possible to
improve the phenotype of aged mdx mice [17]. The investigators
also suggested that the aged mdx mouse is the small animal model
that most closely mimics the severe phenotype of Duchenne
muscular dystrophy (DMD) and therefore is a superior model to
the young mdx mouse when evaluating novel therapeutic strategies
for DMD.
In this study, our goal was to evaluate the effects of angiotensin
receptor blockade (ARB) on both the cardiac and skeletal muscle
phenotype of the aged mdx mouse, and we chose 24 months as an
endpoint. This endpoint seemed ideal based on the existing
literature since it would allow us not only to evaluate cardiac
function at a timepoint after which basal ventricular dysfunction
had been previously reported [14] but also to evaluate the skeletal
muscle phenotype in its most severe state [17]. Our data suggest
that while ARB may be an effective long-term therapy for DMD-
associated cardiomyopathy, it will not be effective as a long-term
treatment for the skeletal muscle disease.
It is unclear why no long term benefit of losartan was observed
in skeletal muscle. It may be that fibrosis early in the disease
process is driven largely by angiotensin II, but that over time, other
pathways become dominant in skeletal muscle. This would allow
the rate of fibrosis to increase despite ARB at a time when
dystrophic satellite cells are experiencing a decline in regenerative
capacity [16]. Future investigation is needed identify these
pathways and to determine the conditions under which losartan
is efficacious in skeletal muscle.
Although we did not observe any benefit of losartan in skeletal
muscle function, cardiac function and geometry was preserved,
and mortality was decreased after two years of angiotensin
receptor blockade. This result is in agreement with a recent study
that demonstrated improved cardiac function, but not improved
skeletal muscle function, following 6 months of losartan treatment
in mdx mice [18]. Our data extend the findings of this previous
study and suggest that angiotensin II signaling is a major
contributor to cardiac disease progression throughout the entire
Figure 5. Expression of conduction-related proteins in the heart at two years. (a) Western blot was performed to quantify levels of the
sodium channel Nav1.5 and gap junction component connexin 40 (Cx40) in the hearts of treated mdx, untreated mdx, and healthy C57 mice. (b)
Nav1.5 expression was significantly decreased in untreated mdx mice compared to healthy C57 controls, and losartan treatment did not restore
Nav1.5 expression. *p,0.05 vs. treated mdx and untreated mdx. (c) Cx40 expression was significantly increased in untreated mdx mice compared to
healthy C57 controls, and losartan treatment normalized expression. *p,0.05 vs. treated mdx and C57 control. Data represent mean6SD.
doi:10.1371/journal.pone.0020856.g005
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disease course. The mechanism underlying this cardiac benefit
may be related to a reduction in fibrosis since we observed an
approximately 20% reduction in cardiac fibrosis with losartan
treatment that trended towards significance (p= 0.08). This is in
agreement with the losartan-mediated reduction in cardiac fibrosis
via TGF-b anatagonism that has been reported in several other
models of cardiomyopathy [18,19,20,21,22]. The reduction in
fibrosis may not have reached significance in our study due to (i)
relatively small study size since five out of nine untreated mice had
died by the two year endpoint, (ii) increased cumulative cardiac
fibrosis in our mice that were 6–12 months older than the mice
studied in previous reports, or (iii) a combination of the two.
Cardiac function may also have been improved by a mechanism
independent from a reduction in fibrosis. Previous studies have
reported that the sodium channel Nav1.5 is decreased in the mdx
heart [23] and that the gap junction component Cx40 is increased
in both the mdx heart [23] and in the hearts of dilated
cardiomyopathy patients [24]. These alterations likely contribute
to the abnormal ECG findings and arrhythmias previously
described in mdx mice [23]. In agreement with these previous
reports, we found that Nav1.5 is decreased and Cx40 increased in
the hearts of mdx mice compared to healthy C57 mice. We also
found that while ARB did not alter expression of Nav1.5, it did
restore Cx40 expression to levels found in the healthy C57 heart.
Therefore, normalization of the function of gap junctions may
contribute to the observed improvement in cardiac function and
reduced mortality in mdx mice treated with ARB. Future
investigation in needed to determine the effect of ARB on
arrythmogenesis and on the abnormal ECG findings in mdx mice
[23].
It has also been reported that defects in calcium handling
secondary to dysregulation of the sarcoplasmic reticulum calcium
ATPase 2a (SERCA2a) and phospholamban (PLB) are present in
the failing hearts of humans and animals [25,26]. Results from a
recent study suggest that ARB in the heart can lead to increased
expression and activity of SERCA2a via modulation of protein
kinase A and Ca2+/calmodulin-dependent protein kinase II
signaling [22]. Further investigation is needed to determine if this
mechanism contributes to improved cardiac function in mdx mice
treated with losartan.
In summary, we report that two years of ARB in the mdx mouse
preserves cardiac function and decreases mortality. No benefit in
terms of skeletal muscle morphology or function was observed,
suggesting that pathway(s) other than angiotensin II are dominant
in driving skeletal muscle fibrosis in late stage disease. In addition,
our study suggests that ARB has potential as a treatment for
DMD-associated cardiomyopathy. Future investigation should be
directed at evaluating losartan in large animal models and patients
with DMD, as well as comparing effectiveness of ARB and
angiotension converting enzyme (ACE) ACE inhibition.
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